TARX (Tarsier Pharma) NonCurrent Deferred Liabilities: $0.00 Mil (As of Dec. 2025)


What is Tarsier Pharma NonCurrent Deferred Liabilities?

Tarsier Pharma TARX NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2025.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Tarsier Pharma's non-current deferred liabilities for the quarter that ended in Dec. 2025 was $0.00 Mil.

Tarsier Pharma NonCurrent Deferred Liabilities Related Terms

Tarsier Pharma NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma NonCurrent Deferred Liabilities Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
0.00 0.00 0.00

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities 0.00 0.00 0.00 0.00 0.00
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Tarsier Pharma (TARX) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's NonCurrent Deferred Liabilities too high?
Tarsier Pharma's current NonCurrent Deferred Liabilities is $0.00 Mil.
How does Tarsier Pharma's NonCurrent Deferred Liabilities compare to ?
Tarsier Pharma's NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.